Discovery Accelerated

BioSymetrics is accelerating early stage drug development by building a more comprehensive view of human health and pharmaceutical research using AI.

NEW Case Study:

Applying Contingent AI to predict targets within the RxRx-19 COVID data set

BioSymetrics is impacting every stage of drug discovery and pharmaceutical research. Roll-over the hot spots below to see how.

TARGET-BASED DRUG DISCOVERY

Applying our ContingentAI framework to clinical data allows for novel gene-disease associations
Our in vivo experimental platform allows us to work in specific genetic contexts, allowing scalable complementation assays
Drug screening leverages our phenotypic barcoding platform, allowing automated lead identification for multi-dimensional phenotype rescue
Predicted off-target effects and toxicity models are used to optimize lead structures

Our target-based approach leverages computational and experimental processes to better predict in vivo efficacy and off-target effects.

PHENOTYPE-BASED DRUG DISCOVERY

Applying our Contingent-AI™ framework to clinical data allows for novel gene-disease associations
Our in vivo experimental platform allows us to work in specific genetic contexts, allowing scalable complementation assays
Drug screening leverages our phenotypic barcoding platform, allowing automated lead identification for multi-dimensional phenotype rescue
Predicted off-target effects and toxicity models are used to optimize lead structures

The Contingent-AI™ computational framework begins with phenotypic screens as input, and predicts molecular mechanism, shortening timelines for target/mechanism identification.

COMPUTATIONAL

Contingent A.I.™

  • Dynamically reduces bias from experimental datasets, including from high-content screening
  • Automated preprocessing of disparate data types (e.g. HCS, proteomics, genomics / transcriptomics) and data sources for faster discovery

EXPERIMENTAL

In Vivo Phenotypic Barcoding

  • We leverage a multi-dimensional “barcode” of in vivo phenotypic characteristics predictive of potential clinical applications and toxicity

AI DRUG DISCOVERY

BioSymetrics Combines Experimental and Machine Learning Methods to Enrich Target-Based Drug Discovery and Shorten Timelines for Phenotype-Based Drug Discovery

Life science companies tend focus on machine learning, ignoring the impact of the decisions they made in collecting and processing their data.

BioSymetrics has built a fundamentally different approach to Data Science, optimizing every step of the pharmaceutical research process using Contingent-AI™.

Pre-processing Artificial Intelligence

The result: less time spent in data processing, easier data integration, more accurate results for diagnostics and drug discovery, as well as truly autonomous capabilities for precision medicine

BioSymetrics Overview (4min)
Webinar – Predicting MOA using AI (Archive).
WATCH THE WEBINAR ARCHIVE
Explore work we are doing in drug repurposing.
COVID-19 INTERACTIVE BLOG

“BioSymetrics is unique in its focus on efficient pre-processing, enabling more transparent model building in biomedicine. We’re excited to be users of the platform.”

Dr. Eric SchadtFounder and CEO, Sema4

“BioSymetrics has supported us in a variety of projects in different settings. In health insurance, their platform saved us months of man hours and approximately $6.4 million (£5-million) annually … the use of Augusta enabled the company to drive faster, more accurate and meaningful innovation.”

Matt HickeyFounder and CEO, Intacare
Recent Blog Posts
December 1, 2020 in Industry News, Press Release

COVID Cloud

Consortium will expand development of a software platform for genomics and health data and apply it to COVID-19. The $5.1M project, called COVID Cloud, aims to increase Canada’s capacity to…
Read More
November 25, 2020 in Event

Hub Xchange Event – AI in Drug Discovery

We are proud to announce that our own Gabe Musso, Chief Science Officer, will be delivering the key note at Hub Xchange's AI in Drug Discovery event on Wednesday, December…
Read More
August 19, 2020 in Corporate News, Drug Discovery, Industry News, Press Release, Press Release

BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19

As part of the collaboration, the parties will use BioSymetrics’ Contingent-AI™ engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and…
Read More
August 18, 2020 in Blog Post, Drug Discovery

Drug Repurposing Prediction Using AI and SARS-CoV-2 High-Content Imaging Screening Data

We were recently approached by a clinical-stage biotech client to investigate one of their lead compounds used to treat COPD. Specifically, we wanted to know whether this compound would have…
Read More